OBJECTIVES: Diagnosis and monitoring of lymphoma includes lymph node assessment. This study examined the association of multiple lymph node biopsies and healthcare resource use among lymphoma patients. METHODS: Patients with ≥2 claims for Hodgkin lymphoma (HL) or non-Hodgkin’s (NHL) lymphoma from 1/1/06-12/31/12 were identified from a large US claims database; the index date was the first lymphoma claim date. Patients were retained if continuously enrolled in the health plan for ≥12 months before and after the index date, were not diagnosed with lymphoma during the pre-index period or diagnosed with cancer other than lymphoma. Healthcare cost and utilization were examined during the 2-year study period. Indication of receipt of biopsy included ≥1 claim for a lymph node biopsy (core needle, fine needle, surgical, other), pathology, or tumor excision (bone marrow biopsy not included). Healthcare cost and utilization was examined among patients with 0 to ≥3 biopsies. The cost of claims indicating biopsy was identified for each biopsy type. RESULTS: